Use of glyburide for the treatment of gestational diabetes: The San Antonio experience

Deborah L Conway, O. Gonzales, D. Skiver

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Objectives: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment. Methods: Women with GDM treated with glyburide were studied. They were divided into two groups: those who achieved adequate glycemic control with glyburide, and those who did not. The groups were compared in terms of baseline characteristics, including diabetes risk factors and glucose testing values. Receiver operating characteristics (ROC) curves were generated to identify thresholds for fasting plasma glucose and body mass index (BMI) that would predict glyburide failure. Results: Seventy-five women were analyzed: 63 (84%) were successfully treated with glyburide, and 12 (16%) were not. Baseline characteristics were similar between the groups, except that failures had higher 3-h glucose tolerance test (GTT) values at all time points. ROC curves for fasting plasma glucose, pre-pregnancy BMI and BMI at diagnosis revealed no cut-off points for predicting failure of glyburide therapy. However, when fasting plasma glucose value on the GTT was ≥ 110 mg/dl, 24% of women failed to respond to glyburide, compared to 12% at < 110 mg/dl (p = 0.15). Conclusions: In treatment of GDM, glyburide is successful in achieving good glycemic control in most women. Women with high fasting plasma glucose levels, however, may not respond adequately to glyburide therapy.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalJournal of Maternal-Fetal and Neonatal Medicine
Volume15
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Gestational Diabetes
Glyburide
Fasting
Glucose
Therapeutics
Body Mass Index
Glucose Tolerance Test
ROC Curve
Treatment Failure
Insulin

Keywords

  • Diabetes
  • Gestation
  • Glyburide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Use of glyburide for the treatment of gestational diabetes : The San Antonio experience. / Conway, Deborah L; Gonzales, O.; Skiver, D.

In: Journal of Maternal-Fetal and Neonatal Medicine, Vol. 15, No. 1, 01.2004, p. 51-55.

Research output: Contribution to journalArticle

@article{53b5f73482024b94ab2b66b09fdcae21,
title = "Use of glyburide for the treatment of gestational diabetes: The San Antonio experience",
abstract = "Objectives: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment. Methods: Women with GDM treated with glyburide were studied. They were divided into two groups: those who achieved adequate glycemic control with glyburide, and those who did not. The groups were compared in terms of baseline characteristics, including diabetes risk factors and glucose testing values. Receiver operating characteristics (ROC) curves were generated to identify thresholds for fasting plasma glucose and body mass index (BMI) that would predict glyburide failure. Results: Seventy-five women were analyzed: 63 (84{\%}) were successfully treated with glyburide, and 12 (16{\%}) were not. Baseline characteristics were similar between the groups, except that failures had higher 3-h glucose tolerance test (GTT) values at all time points. ROC curves for fasting plasma glucose, pre-pregnancy BMI and BMI at diagnosis revealed no cut-off points for predicting failure of glyburide therapy. However, when fasting plasma glucose value on the GTT was ≥ 110 mg/dl, 24{\%} of women failed to respond to glyburide, compared to 12{\%} at < 110 mg/dl (p = 0.15). Conclusions: In treatment of GDM, glyburide is successful in achieving good glycemic control in most women. Women with high fasting plasma glucose levels, however, may not respond adequately to glyburide therapy.",
keywords = "Diabetes, Gestation, Glyburide",
author = "Conway, {Deborah L} and O. Gonzales and D. Skiver",
year = "2004",
month = "1",
doi = "10.1080/14767050310001650725",
language = "English (US)",
volume = "15",
pages = "51--55",
journal = "Journal of Maternal-Fetal and Neonatal Medicine",
issn = "1476-7058",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Use of glyburide for the treatment of gestational diabetes

T2 - The San Antonio experience

AU - Conway, Deborah L

AU - Gonzales, O.

AU - Skiver, D.

PY - 2004/1

Y1 - 2004/1

N2 - Objectives: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment. Methods: Women with GDM treated with glyburide were studied. They were divided into two groups: those who achieved adequate glycemic control with glyburide, and those who did not. The groups were compared in terms of baseline characteristics, including diabetes risk factors and glucose testing values. Receiver operating characteristics (ROC) curves were generated to identify thresholds for fasting plasma glucose and body mass index (BMI) that would predict glyburide failure. Results: Seventy-five women were analyzed: 63 (84%) were successfully treated with glyburide, and 12 (16%) were not. Baseline characteristics were similar between the groups, except that failures had higher 3-h glucose tolerance test (GTT) values at all time points. ROC curves for fasting plasma glucose, pre-pregnancy BMI and BMI at diagnosis revealed no cut-off points for predicting failure of glyburide therapy. However, when fasting plasma glucose value on the GTT was ≥ 110 mg/dl, 24% of women failed to respond to glyburide, compared to 12% at < 110 mg/dl (p = 0.15). Conclusions: In treatment of GDM, glyburide is successful in achieving good glycemic control in most women. Women with high fasting plasma glucose levels, however, may not respond adequately to glyburide therapy.

AB - Objectives: Equivalent efficacy of glyburide and insulin for treatment of gestational diabetes (GDM) was demonstrated in a recent randomized trial. We describe our experience with glyburide in practice, and suggest factors that predict failure of glyburide treatment. Methods: Women with GDM treated with glyburide were studied. They were divided into two groups: those who achieved adequate glycemic control with glyburide, and those who did not. The groups were compared in terms of baseline characteristics, including diabetes risk factors and glucose testing values. Receiver operating characteristics (ROC) curves were generated to identify thresholds for fasting plasma glucose and body mass index (BMI) that would predict glyburide failure. Results: Seventy-five women were analyzed: 63 (84%) were successfully treated with glyburide, and 12 (16%) were not. Baseline characteristics were similar between the groups, except that failures had higher 3-h glucose tolerance test (GTT) values at all time points. ROC curves for fasting plasma glucose, pre-pregnancy BMI and BMI at diagnosis revealed no cut-off points for predicting failure of glyburide therapy. However, when fasting plasma glucose value on the GTT was ≥ 110 mg/dl, 24% of women failed to respond to glyburide, compared to 12% at < 110 mg/dl (p = 0.15). Conclusions: In treatment of GDM, glyburide is successful in achieving good glycemic control in most women. Women with high fasting plasma glucose levels, however, may not respond adequately to glyburide therapy.

KW - Diabetes

KW - Gestation

KW - Glyburide

UR - http://www.scopus.com/inward/record.url?scp=2542482790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542482790&partnerID=8YFLogxK

U2 - 10.1080/14767050310001650725

DO - 10.1080/14767050310001650725

M3 - Article

C2 - 15101612

AN - SCOPUS:2542482790

VL - 15

SP - 51

EP - 55

JO - Journal of Maternal-Fetal and Neonatal Medicine

JF - Journal of Maternal-Fetal and Neonatal Medicine

SN - 1476-7058

IS - 1

ER -